Epilepsy Therapeutics Market - Global Industry Perspective Comprehensive Analysis and Forecast, 2015 to 2021

Report Code: ZMR-91 | Report Format : | Status : Upcoming |

Abstract

Epilepsy is a chronic neurological disorder characterized by unpredictable seizures. Epilepsy is the fourth most common neurological disorder that affects peoples of all age group. Seizures may be classified as focal seizures, generalized seizures, and other seizures. Focal seizures are the most common type of epilepsy which involves secondary generalized tonic/clonic seizures (sGTCS) and complex partial seizures. Generalized seizures include myoclonic seizures, tonic seizures, atonic seizures, absences, and clonic seizures. These seizures occur when neurons in the brain or a group of nerve cells send wrong signals to the body.

Treatment of epilepsies is done by using antiepileptic drugs (AEDs). Antiepileptic drugs are segmented into two major categories namely first generation AEDs and second generation AEDs. Selection of drugs is done by prescriber depending upon the type of seizure, part of brain involved in epilepsy, age of patient.

Epilepsy therapeutic drug market is mostly driven by increasing prevalence of neurological disorders and technological advancements across many countries. Moreover, increasing awareness about diagnostics and treatment of neurological disorders in global market also help in driving the epileptic market growth. Non availability of medical facilities in poor and developing countries can restrict or hinder the growth of epileptic therapeutic market over the years. Conversely, the prescribing pattern of drugs that give preference to first generation AEDs over second generation AEDs is restraining the epilepsy therapeutics market. Nonetheless, ongoing research and development in the healthcare literacy rate are expected to open growth avenues for the market over the years.

The report covers forecast and analysis of the epileptic therapeutic market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016 to 2021 based on revenue (USD Million).  To understand the competitive landscape in the market, an analysis of Porter’s Five Forces model for the epileptic therapeutic drug market has also been included in the study. The report also analyzes several driving and restraining factors and their impact on the market during the forecast period. The study encompasses a market attractiveness analysis, wherein type segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides detailed segmentation of the epileptic therapeutic drug market based on type and regional segment.

Geographically, the market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Demand has been analyzed and forecast based on the current trends for the period of six years. North America & Europe were the leading regional segments of the epileptic therapeutic drug market due to availability of second generation antiepileptic drug.

Three new AEDs have been approved in the U.S. since 2012 including ezogabine/retigabine, perampanel and eslicarbazepine acetate. Ezogabine/retigabine and perampanel among these have new mechanism of action and thus it is capturing good amount of market share in the U.S. The epileptic therapeutic market is expected to witness the highest growth in the Asia-Pacific region in the coming years due to high prevalence of epilepsy in India and China, increasing health care infrastructure, incomes and awareness.

Key players in epileptic therapeutic market include Abbott Laboratories, GlaxoSmithKline plc, Cephalon, Inc., Johnson & Johnson, Pfizer, Inc., Novartis AG, Sunovion Pharmaceuticals, Inc.., Valeant Pharmaceuticals International, Inc., Sanofi S.A. and Shire.

This report segments the epileptic therapeutic market are:-

Epilepsy Therapeutics Market: Type Segment Analysis

  • First Generation
  • Second Generation

Epilepsy Therapeutics Market: Regional Segment Analysis

  • North America
  • Europe
  • Asia pacific
  • Latin America
  • Middle east & Africa

Related Reports

Contrast Media/Contrast Agent Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-1359 | Report Format:

Global Contrast Media/Contrast Agent Market: Overview To enhance the contrast of the structures or fluids inside the body contrast medium or the contrast agent is used in the medical imaging. The anatomical organs and structures are imaged better as the image contrast is increased. Thus, it is v...Read More

Continuous Renal Replacement Therapy (CRRT) Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-1358 | Report Format:

Global Continuous Renal Replacement Therapy (CRRT) Market: Overview A process wherein extracorporeal blood purification is done to substitute for the renal dysfunction for an extended period of time is known as continuous renal replacement therapy (CRRT). It is a therapy of renal replacement for...Read More

Superdisintegrants Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-1354 | Report Format:

Global Superdisintegrants Market: Overview Superdisintegrant is a kind of excipient that is used for the tablet-based drug delivery in the pharmaceutical industry. To help the solid dosage form drugs such as pills or tablets disintegrate when they are submerged in the liquid superdisintegrants a...Read More

Medication Management Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 2016–2024

Price : $ 3599.00 | Report Code: ZMR-1349 | Report Format:

Global Medication Management Market: Overview To manage and support the medicine management cycle an advanced system is developed known as medication management. In the hospitals, the medication management system is used for prescribing, supplying and administering the medicines. The use of the ...Read More

Hepatitis C Drug Market for Hospitals, Private labs, Physician Offices, Public Health Labs and Blood Banks - Global Industry Perspective, Comprehensive Analysis and Forecast, 2016 – 2022

Mar-2017 | Price : $ 4199.00 | Pages: 110 | Report Code: ZMR-1326 | Report Format:

The report covers forecast and analysis for the Hepatitis C drug market on a global and regional level. The study provides historic data of 2016 along with a forecast from 2017 to 2022 based on revenue (USD Billion). The study includes drivers and restraints for the Hepatitis C drug market along w...Read More

Choose License Type: